These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 216371)

  • 1. Effect of theophylline and other drugs on rabbit renal cyclic nucleotide phosphodiesterase, 5'-nucleotidase and adenosine deaminase.
    Fredholm BB; Hedqvist P; Vernet L
    Biochem Pharmacol; 1978; 27(24):2845-50. PubMed ID: 216371
    [No Abstract]   [Full Text] [Related]  

  • 2. A simple direct assay of 3',5'-cyclic nucleotide phosphodiesterase activity based on the use of polyacrylamide-bononate affinity gel chromatography.
    Davis CW; Daly JW
    J Cyclic Nucleotide Res; 1979; 5(1):65-74. PubMed ID: 220290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic nucleotide phosphodiesterase activity: histochemical and cytochemical methods.
    Ueno S; Ueck M
    Methods Enzymol; 1988; 159():477-89. PubMed ID: 2842613
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibitory effects of cromoglycate and theophylline on rat macrophage and mast-cell cyclic nucleotide phosphodiesterase [proceedings].
    Saeed SA; Butt NM; Sheldon D; Taylor WA
    Biochem Soc Trans; 1979 Dec; 7(6):1304-6. PubMed ID: 231532
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from pig coronary arteries by 1,3-disubstituted and 1,3,8-trisubstituted xanthines.
    Wells JN; Garst JE; Kramer GL
    J Med Chem; 1981 Aug; 24(8):954-8. PubMed ID: 6276544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of phosphodiesterase inhibitors, imidazole and phosphate on cyclic CMP phosphodiesterase are different from those on cyclic AMP and cyclic GMP phosphodiesterases.
    Kuo JF; Shoji M; Brackett NL; Helfman DM
    J Cyclic Nucleotide Res; 1978 Dec; 4(6):463-74. PubMed ID: 85641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic nucleotide phosphodiesterase in normal and leukemic human lymphocytes and lymphoblasts.
    Epstein PM; Hachisu R
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():303-24. PubMed ID: 6202124
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclic nucleotide phosphodiesterase in heart and aorta of spontaneously hypertensive rats.
    Sharma RV; Bhalla RC
    Biochim Biophys Acta; 1978 Oct; 526(2):479-88. PubMed ID: 214127
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclic 3',5'-adenosine monophosphate phosphodiesterase (cAMP PDE) and cyclic 3',5'-guanosine monophosphate phosphodiesterase (cGMP PDE) in microvessels isolated from bovine cortex.
    Stefanovich V
    Neurochem Res; 1979 Dec; 4(6):681-7. PubMed ID: 232543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rat brain and lung cyclic nucleotide phosphodiesterases: different responses to cromoglycate [proceedings].
    Saeed SA; Butt NM; Taylor WA
    Biochem Soc Trans; 1979 Oct; 7(5):1037-8. PubMed ID: 229020
    [No Abstract]   [Full Text] [Related]  

  • 11. The distribution of cyclic nucleotide phosphodiesterase in the hypothalamus.
    Howlett AC; Breckenridge BM
    J Neurochem; 1978 Jul; 31(1):321-7. PubMed ID: 209146
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclic nucleotide phosphodiesterase of normal and leukemic lymphocytes. Kinetic properties and selective alteration of the activity of the multiple molecular forms.
    Hait WN; Weiss B
    Mol Pharmacol; 1979 Nov; 16(3):851-64. PubMed ID: 231197
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
    Liao CH; Tzeng CC; Teng CM
    Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General properties of multiple molecular forms of cyclic nucleotide phosphodiesterase in the nervous system.
    Strada SJ; Martin MW; Thompson WJ
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():13-29. PubMed ID: 6326518
    [No Abstract]   [Full Text] [Related]  

  • 16. Myofibrillar bound cyclic nucleotide phosphodiesterase in heart and skeletal muscle.
    Worby A; Mensah LM; Murray KJ
    Biochem Soc Trans; 1992 May; 20(2):129S. PubMed ID: 1327896
    [No Abstract]   [Full Text] [Related]  

  • 17. Cyclic nucleotide phosphodiesterases: critical modulators of endocrine, metabolic, and cardiovascular function and appealing therapeutic targets.
    Manganiello V
    Curr Opin Pharmacol; 2011 Dec; 11(6):646-8. PubMed ID: 22079477
    [No Abstract]   [Full Text] [Related]  

  • 18. Characteristics of the cyclic nucleotide phosphodiesterases in a transplantable pheochromocytoma and adrenal medulla of the rat.
    Levin RM; Weiss B
    Cancer Res; 1978 Apr; 38(4):915-20. PubMed ID: 205349
    [No Abstract]   [Full Text] [Related]  

  • 19. The response of cyclic 3',5'-AMP and cyclic 3',5'-GMP phosphodiesterases to experimental diabetes.
    Perez de Gracia B; Rhoads AR; West WL
    Experientia; 1980 Jul; 36(7):824-5. PubMed ID: 6249634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membraneous and cytosolic cyclic-nucleotide phosphodiesterases in beef aorta: substrate specificity, endogenous inhibition and activation [proceedings].
    Ilien B; Morel A; Stierle A; Landry Y
    Arch Int Physiol Biochim; 1978 Oct; 86(4):865-7. PubMed ID: 84582
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.